Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2007 | 1 |
2009 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
I-Tositumomab in lymphoma.
Curr Oncol. 2009 Sep;16(5):32-47.
Curr Oncol. 2009.
PMID: 19862360
Free PMC article.
Initial studies of (131)I-tositumomab in non-Hodgkin lymphoma (NHL) have suggested benefit in patients with relapsed or refractory indolent disease. However, the routine adoption of this agent is tempered by concerns about associated toxicities and unclear long-term benefi …
Initial studies of (131)I-tositumomab in non-Hodgkin lymphoma (NHL) have suggested benefit in patients with relapsed or refractory indolent …
Temozolomide for the treatment of metastatic melanoma.
Quirbt I, Verma S, Petrella T, Bak K, Charette M; Members of the Melanoma Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care.
Quirbt I, et al.
Curr Oncol. 2007 Feb;14(1):27-33. doi: 10.3747/co.2007.98.
Curr Oncol. 2007.
PMID: 17576461
Free PMC article.
To provide treatment recommendations for this new agent, the Melanoma Disease Site Group (dsg) of Cancer Care Ontario's Program in Evidence-Based Care (pebc) decided to review the available literature on single-agent temozolomide and on temozolomide in combin …
To provide treatment recommendations for this new agent, the Melanoma Disease Site Group (dsg) of Cancer Care Ontario's …
Item in Clipboard
Cite
Cite